GI 254023X: Selective ADAM10 Inhibitor for Precise Sheddase Modulation

Executive Summary: GI 254023X is a small-molecule, nanomolar-potency inhibitor of ADAM10 metalloprotease, with >100-fold selectivity over ADAM17, enabling precise dissection of ADAM10-dependent signaling pathways (APExBIO, product page). It blocks ADAM10-mediated cleavage of substrates such as fractalkine (CX3CL1) and protects endothelial barriers from Staphylococcus aureus α-hemolysin (Hla)-induced disruption in vitro and in vivo (Satir et al., 2020). The compound induces apoptosis in Jurkat T-lymphoblastic leukemia cells and modulates Notch1 signaling and MCL-1 expression (APExBIO). GI 254023X is suitable for acute studies in vascular, leukemia, and signaling models but not for chronic in vivo use due to metabolic instability. All claims are supported by peer-reviewed data and product documentation.

Biological Rationale

ADAM10 (A Disintegrin And Metalloproteinase domain-containing protein 10; EC 3.4.24.81) is a transmembrane metalloprotease responsible for the proteolytic release ('shedding') of diverse cell surface proteins. Key substrates include Notch1, fractalkine (CX3CL1), VE-cadherin, and amyloid precursor protein (APP) (Satir et al., 2020). ADAM10 activity is central to cell-cell adhesion, immune response, and signaling events in both physiological and pathological contexts. Dysregulated ADAM10 activity is implicated in cancer, neurodegeneration, and vascular barrier disruption. Selective inhibition of ADAM10 provides a means to dissect its functions without confounding effects from related metalloproteases, notably ADAM17.

Mechanism of Action of GI 254023X

GI 254023X is a non-peptidic, small-molecule inhibitor with a molecular weight of 391.5 Da and chemical formula C₂₁H₃₃N₃O₄ (APExBIO). It inhibits ADAM10 sheddase activity with an IC₅₀ of 5.3 nM in enzymatic assays. The compound demonstrates >100-fold selectivity for ADAM10 over ADAM17. Mechanistically, GI 254023X binds to the catalytic site of ADAM10, preventing the proteolytic cleavage of substrates such as fractalkine and Notch1. In cellular models, this inhibition leads to reduced Notch1 activation, decreased MCL-1 expression, and induction of apoptosis in T-lymphoblastic leukemia cells. In endothelial cells, GI 254023X blocks VE-cadherin cleavage and preserves barrier integrity during bacterial toxin challenge.

Evidence & Benchmarks

• GI 254023X inhibits recombinant ADAM10 with an IC₅₀ of 5.3 nM at 25°C in buffered enzymatic assays (APExBIO).
• Exhibits >100-fold selectivity over ADAM17, minimizing off-target metalloprotease effects (APExBIO).
• Blocks ADAM10-mediated cleavage of fractalkine (CX3CL1) and Notch1 in cell culture models (Satir et al., 2020).
• Induces apoptosis and reduces proliferation in Jurkat T-lymphoblastic leukemia cells by modulating Notch1 and MCL-1 expression (APExBIO).
• Prevents VE-cadherin cleavage and endothelial barrier disruption in HPAECs exposed to Staphylococcus aureus α-hemolysin (APExBIO).
• Enhances vascular integrity and survival in BALB/c mice after lethal bacterial toxin challenge (200 mg/kg/day, i.p., 3 days) (APExBIO).
• Does not inhibit β-secretase (BACE1) or alter amyloid β generation under experimental conditions tested (Satir et al., 2020).

This article expands on findings in GI 254023X: Selective ADAM10 Inhibitor for Precision Rese... by detailing quantitative parameters and in vivo outcomes, providing a benchmark for mechanistic studies.

Applications, Limits & Misconceptions

GI 254023X is a research-grade tool for acute inhibition of ADAM10 activity in cellular and animal models. Major application areas include:

• Leukemia research: Induces apoptosis in Jurkat cells, allowing mechanistic dissection of Notch1-dependent survival pathways.
• Vascular biology: Prevents VE-cadherin cleavage and protects endothelial integrity under bacterial toxin stress.
• Cell signaling: Dissects ADAM10-dependent Notch1 activation and substrate shedding.

GI 254023X is unsuitable for chronic therapeutic studies due to metabolic instability and lack of clinical data. It does not inhibit BACE1 or γ-secretase, and cannot be used as an amyloid β-lowering agent. This article clarifies and updates mechanistic boundaries set in GI 254023X (SKU A4436): Optimizing ADAM10 Inhibition in C... by outlining selectivity and workflow parameters.

Common Pitfalls or Misconceptions

• Not a pan-metalloprotease inhibitor: GI 254023X does not broadly inhibit all ADAM or MMP family members; selectivity is >100-fold for ADAM10 over ADAM17 and negligible for others.
• Ineffective at chronic dosing: The compound is metabolically unstable in vivo, limiting use to acute or short-course experiments.
• Not a BACE1/γ-secretase inhibitor: GI 254023X does not block β- or γ-secretase activity or significantly alter amyloid β generation (Satir et al., 2020).
• Solubility constraints: GI 254023X is insoluble in water; DMSO or ethanol are required for stock preparation.
• For research use only: Not intended for therapeutic or diagnostic use in humans.

The present review extends mechanistic insight beyond GI 254023X: Precision ADAM10 Inhibition for Novel Disease... by providing quantitative evidence and workflow-specific cautions.

Workflow Integration & Parameters

• Solubilization: GI 254023X is soluble at ≥42.6 mg/mL in DMSO and ≥46.1 mg/mL in ethanol; insoluble in water.
• Stock preparation: Prepare stocks >10 mM in DMSO; warming and sonication aid dissolution.
• Storage: Store powder at –20°C. Avoid long-term storage of solutions; prepare fresh aliquots as needed.
• Working concentrations: Use 10–200 nM in vitro for cell-based assays. For in vivo mouse studies, 200 mg/kg/day i.p. for 3 days is validated (APExBIO).
• Controls: Always include DMSO-only vehicle controls to confirm specificity.

For scenario-driven best practices and workflow troubleshooting, see GI 254023X (SKU A4436): Scenario-Driven Solutions for ADA.... This article provides new quantitative validation and clarifies assay boundaries.

Conclusion & Outlook

GI 254023X (SKU A4436) from APExBIO is the leading research tool for selective, high-potency inhibition of ADAM10 sheddase activity. Its well-characterized selectivity profile and robust efficacy in cell and animal models make it indispensable for studies in vascular biology, leukemia, and cell signaling. However, its use is limited to acute experimental paradigms due to metabolic and solubility constraints. Proper workflow integration ensures reproducibility and minimizes off-target effects. Ongoing preclinical research will further define the translational boundaries and mechanistic depth of selective ADAM10 inhibition. For detailed protocols and updated benchmarks, refer to the GI 254023X product page at APExBIO.